Viewing Study NCT06639711



Ignite Creation Date: 2024-10-26 @ 3:42 PM
Last Modification Date: 2024-10-26 @ 3:42 PM
Study NCT ID: NCT06639711
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: None
First Post: 2024-10-10

Brief Title: Taurine Eye Drops May Prevent the Progression of Cataract
Sponsor: None
Organization: None

Study Overview

Official Title: Taurine Affects the Progression of Senile Cataract a Single-arm Pre-post Intervention Study
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops available under brand name VIZILOTON to prevent the progression of grade I and II senile cataract

This study could answer

Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract
The acceptance compliance of participants to taurine-containing eye drops
Could long-term use of taurine-containing eye drops cause adverse effects

Participants will

Take taurine-containing eye drops VIZILOTON eye drops 4 times a day for one year
Visit eye clinic every 3 months for assessment and visual examination
Keep notes for their symptoms and their adherence to treatment
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None